TODAY'S HEADLINES
Allergan’s board of directors has unanimously rejected a May 30 bid of $54 billion from Valeant Pharmaceuticals International and Pershing Square Capital Management. Valeant and Pershing originally made an unsolicited $47 billion offer in April, which Allergan also rebuffed. » More
|
|
In separate studies, researchers in France and the United States have found that the more moles a woman has, the greater her risk of breast cancer. » More
|
|
fyi...
|
30,000 |
|
Physicians dropped from UnitedHealth Group’s Medicare Advantage Network Source: Medical Economics
|
|
|
The Food and Drug Administration has granted marketing clearance for Restylane Silk (Valeant), an injectable gel containing 0.3 percent lidocaine, for lip augmentation and perioral rhytids in patients age 21 and older. » More
|
|
Botulinum toxin type A may provide a reasonable therapeutic option for some patients with rosacea according to experts who spoke at the Orlando Dermatology meeting recently. » More
|
|
|
Like
Tweet
